Integrated analysis reveals prognostic value of HLA-I LOH in triple-negative breast cancer
Background Triple-negative breast cancers (TNBCs), especially those non-immune-inflamed tumors, have a poor prognosis and limited therapies. Human leukocyte antigen (HLA)-I not only contributes to antitumor immune response and the phenotype of the tumor microenvironment, but also is a negative predi...
Saved in:
| Main Authors: | Yi Xiao, Xi Jin, Yi-Zhou Jiang, Zhi-Ming Shao, Yi-Fan Zhou, Gen-Hong Di |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-10-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/9/10/e003371.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
LOH at 1p31 (ARHI) and Proliferation in Lymph Node-Negative Breast Cancer
by: Emiel A. M. Janssen, et al.
Published: (2009-01-01) -
Copy number amplification of FLAD1 promotes the progression of triple-negative breast cancer through lipid metabolism
by: Xiao-Qing Song, et al.
Published: (2025-02-01) -
Identification of circulating tumor cells marker genes as prognostic signature in triple-negative breast cancer
by: Jia Hu, et al.
Published: (2025-05-01) -
Prognostic Value of Trop‐2 Expression in Nonmetastatic Triple‐Negative Breast Cancer and Correlation With Emerging Biomarkers
by: William Jacot, et al.
Published: (2025-03-01) -
Single-cell ligand–receptor profiling reveals an immunotherapy-responsive subtype and prognostic signature in triple-negative breast cancer
by: Chuanzhi Chen, et al.
Published: (2025-06-01)